SecBot SecBot
PRESS-RELEASE ·Filed Mar 23, 2026

CABA

Cabaletta Bio
NEUTRAL
Impact 5/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Monitor upcoming Phase 1/2 data readouts in 1H26, particularly from RESET-SLE and RESET-SSc, which could inform registrational pathways and potentially catalyze investor interest despite lack of near-term revenue.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$2.82
T+0 close · Mar 23, 2026 · via day close
Latest settled
+0.71%
T+60 · $2.84
Vs SPY
−12.35%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 23 $2.82entry
  2. T+1 · 8mo ago −5.32%α −4.96% · $2.67
  3. T+5 · 8mo ago −12.41%α −8.85% · $2.47
  4. T+20 · 7mo ago +10.99%α +3.57% · $3.13
  5. T+60 · 5mo ago +0.71%α −12.35% · $2.84
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Cabaletta Bio reported Q4 and full-year 2025 financial results, highlighted by increased R&D spending and a cash position of $133.6 million, sufficient to fund operations into Q4 2026. The company reiterated key clinical milestones for rese-cel, including complete Phase 1/2 data readouts in 1H26 and a planned BLA submission for myositis in 2027.

Key Financial Metrics

EPS
$-2.10

Key Facts

  • R&D expenses increased to $36.2M (Q4 2025) from $25.5M (Q4 2024); full-year R&D rose to $142.7M from $97.2M.
  • G&A expenses decreased to $6.4M (Q4 2025) from $8.3M (Q4 2024).
  • Cash, cash equivalents, and short-term investments totaled $133.6M as of December 31, 2025, down from $164.0M a year prior.
  • Company raised an additional $30.0M in Q1 2026 via ATM sales and warrant exercises.
  • Cash runway expected through Q4 2026.
  • Complete Phase 1/2 data from RESET-SLE, RESET-SSc, and RESET-MG trials expected in 1H26.
  • BLA submission for rese-cel in myositis anticipated in 2027 based on 17-patient registrational cohort.

Financial Impact

Increased R&D spend by $45.5M year-over-year; net loss widened to $167.9M in 2025 from $115.9M in 2024.

r_and_d_expensenet_losscash_position

Risk Factors

  • High cash burn with no approved products; dependent on successful clinical outcomes and future financing.
  • Clinical timelines are forward-looking and subject to delays; no guarantee that data will support BLA submission or approval.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3260280

Track record

29 reports on CABA

Performance horizon

4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +31.59% at T+60 after the May 4, 2026 report. 5 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $1.15 Now $1.11 −3.09% settles Nov 23
  2. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.32 Now $1.11 −15.91% settles Nov 23
  3. Nov 12, 20264d ago SC 13G/A Neutral 2/10 Entry $1.33 Now $1.11 −16.54% settles Nov 19
  4. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $1.45 Now $1.11 −23.45% settles Nov 17
  5. Nov 9, 20267d ago 8-K Bullish 6/10 Entry $1.50 to $1.11 Now $1.11 −26.00% ▼ −26.00% −24.31% vs SPY
  6. Nov 8, 20268d ago Press Release Bullish 6/10 Entry $1.50 to $1.11 Now $1.11 −26.00% ▼ −26.00% −24.31% vs SPY
  7. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $1.30 to $1.28 Now $1.11 −14.62% ▼ −1.54% −4.13% vs SPY
  8. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $1.30 to $1.28 Now $1.11 −14.62% ▼ −1.54% −4.13% vs SPY
  9. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $1.28 to $1.33 Now $1.11 −13.28% ▲ +3.91% +0.62% vs SPY
  10. Nov 5, 202611d ago Press Release Neutral 4/10 No price data
Showing 10 of 29

US Market Status

Market Closed · Opens in 6h 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 23, 2026